Immatics N.V. (IMTX)
NASDAQ: IMTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IMTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $878.58M
- EPS (TTM)
- -$1.95
- Dividend yield
- None
- 52-week range
- 5.72 – 12.41
- Day range
- 5.72 – 5.95
- Volume / Avg
- 746.64K / 962.74K
- Beta
- —
- Shares outstanding
- 152.27M
52-week range
IMTX stock today
On Nov 20, IMTX ended the session at $5.77, shedding $0.18 (3.03%), versus the S&P 500's 3.70% decline. At this level, IMTX sits near the bottom of its 52-week range of $5.72 to $12.41: 53.5% below the high, set on Dec 4, 2025 and 1.0% above the low. IMTX is down 45.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 43.4%.
Immatics N.V. has posted a net loss over the last twelve months (EPS of -$1.95), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Immatics N.V.
Company profileImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Harpreet Singh Ph.D.
- Headquarters
- Tübingen
- Employees
- 721
- Website
- immatics.com
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$15.97+176.78%
- Strong buy 0
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.58 vs $-0.49
- Surprise
- -18.37%
IMTX news
All IMTX news- Immatics Announces Third Quarter 2026 Financial Results and Business UpdateGlobeNewswire
- Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat EstimatesNasdaqBMY, IMTX
- Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual MeetingGlobeNewswire
- Immatics N.V. Announces Updated Phase 1 Data for IMA203CD8 with 51% Objective Response RateNasdaqIMTX, BF.A
- Stifel Initiates Coverage of Immatics N.V. at BuyNasdaq
- Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpNasdaqINO, MDGL, IMTX
Immatics N.V. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ODTXOdyssey Therapeutics Inc. | 16.96 | -7.52% | $815.23M | vs IMTX |
| BBTXBambusa Therapeutics Inc. | 16.00 | +2.89% | $815.08M | vs IMTX |
| PRMEPrime Medicine Inc. | 3.55 | -7.55% | $791.62M | vs IMTX |
| MGTXMeiraGTx Holdings plc | 7.98 | -1.97% | $779.89M | vs IMTX |
| INBXInhibrx Biosciences Inc. | 68.97 | -7.21% | $1.02B | vs IMTX |
| GLUEMonte Rosa Therapeutics Inc. | 8.64 | -3.03% | $738.29M | vs IMTX |
| AURAAura Biosciences Inc. | 6.87 | -1.58% | $714.99M | vs IMTX |
| SLDBSolid Biosciences Inc. | 6.25 | -2.95% | $697.57M | vs IMTX |
Indexes, lists and sector
Immatics N.V. stock FAQ
What is Immatics N.V.'s stock price today?
IMTX last traded at $5.77 as of Nov 20, 4:00 PM EST, down 3.03% on the day. Prices are delayed at least 15 minutes.
Who is Immatics N.V.'s CEO?
Dr. Harpreet Singh Ph.D. is the chief executive officer of Immatics N.V., which has about 721 employees.
What is the IMTX 52-week high?
The 52-week high for IMTX is $12.41 and the 52-week low is $5.72. The stock is currently 53.5% below its high.